Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study
Open Access
- 1 August 2000
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 13 (8) , 899-906
- https://doi.org/10.1016/s0895-7061(00)00280-6
Abstract
The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effeKeywords
This publication has 11 references indexed in Scilit:
- Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic HypertensionNew England Journal of Medicine, 1999
- Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialThe Lancet, 1999
- Characteristics of 9194 Patients With Left Ventricular HypertrophyHypertension, 1998
- Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39BMJ, 1998
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 1998
- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 1998
- Calcium-Channel Blockers for Hypertension — Uncertainty ContinuesNew England Journal of Medicine, 1998
- The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureArchives of internal medicine (1960), 1997
- DiscussionAmerican Journal of Hypertension, 1997
- Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society.BMJ, 1993